Brief: Myriad Genetics Q2 EPS USD -3.57

Myriad Genetics

05/08/2025 21:05

Overview

Myriad Q2 2025 revenue rises 1% yr/yr, beating analyst expectations, per LSEG data

Adjusted EPS for Q2 2025 beats consensus, per LSEG data

Co on July 31, entered $200 mln credit facility

Co raises 2025 revenue guidance

Outlook

Company raises 2025 revenue guidance to $818 - $828 mln

Myriad Genetics maintains 2025 adjusted EPS guidance of $(0.02) - $0.02

Myriad Genetics aims high single-digit to low double-digit revenue growth over the next five years

Result Drivers

HEREDITARY CANCER TESTING - Revenue and volume in Oncology grew 9% and 10% yr/yr, driven by MyRisk with RiskScore testing

GROSS MARGIN IMPROVEMENT - Gross margin increased over 160 basis points yr/yr, benefiting from product mix and laboratory efficiencies

HEADWINDS EXCLUSION - Excluding $9.5 mln headwinds, revenue increased 5% yr/yr, attributed to UNH coverage discontinuation and EndoPredict divestiture

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$213.10 mln
$201.90 mln (15 Analysts)
Q2 Adjusted EPS
Beat
$0.05
-$0.01 (14 Analysts)
Q2 EPS
-$3.57
Q2 Net Income
-$330.50 mln
Q2 Gross Margin
71.2%
Q2 Adjusted Operating Income
Beat
$8.60 mln
-$556,400 (10 Analysts)
Q2 Adjusted Operating Expenses
$143.80 mln
Q2 Operating Expenses
$481 mln
Q2 Operating Income
-$329.20 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 9 "hold" and 4 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Myriad Genetics Inc is $6.00, about 33.7% above its August 4 closing price of $3.98

The stock recently traded at 51 times the next 12-month earnings vs. a P/E of 52 three months ago

Press Release: ID:nGNX9JCtqW

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)